Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Pandemics and Biosecurity
3OCT

Ebola cases pass 1,481 as isolation lags

3 min read
13:42UTC

WHO's DON612 put the Bundibugyo outbreak at 1,481 confirmed cases and 454 deaths on 3 July, with patient isolation near 44 percent, still short of the level modelling says would break transmission.

ScienceDeveloping
Key takeaway

WHO's DON612 logged 1,481 Bundibugyo cases with isolation near 44 percent, still short of the model's 70 percent fork.

WHO Disease Outbreak News DON612, published Friday 3 July, put the Bundibugyo outbreak at 1,481 confirmed cases, with 1,460 in DR Congo, 20 in Uganda and one in France, alongside 454 deaths and a case-fatality ratio of 30.9 percent⁠1. That is a 35 percent rise in nine days, up from the 1,094 cases logged on 24 June.

The patient-isolation rate, the share of confirmed patients kept in isolation, rose from 35 percent on 24 June to about 44 percent by 30 June, or 641 of 1,460 DRC patients, per South Africa's National Institute for Communicable Diseases and the EU's disease-control agency, the ECDC⁠2. That sits well short of the 70 percent at which the CDC model, built on a reproduction number of 2.51, collapses its worst case to a one-in-a-hundred tail. Contact-tracing follow-up, a separate figure meaning how many listed contacts are actually visited, climbed from 21 percent to 83.2 percent in Ituri and 81 percent in North Kivu. Isolation decides whether transmission breaks; follow-up only builds the list of WHO to watch.

Most of those cases now trace back through the hospitals meant to contain them. 102 healthcare workers have been infected in DRC and 25 have died, up from the 34 infections counted in mid-June. This is nosocomial spread, transmission inside care settings, and it has been the outbreak's hardest edge since the first nurses died at Mongbwalu in May.

Cases are still climbing and isolation still trails 70 percent, so the outbreak sits on the high-case-count side of the model's fork even as both operational numbers improve. The move from 35 to 44 percent buys less than the remaining climb to 70 will, because the CDC curve is non-linear, with most of the outbreak-ending benefit concentrated between roughly 50 and 70 percent. Two operational numbers improved this week; patient isolation, the one that decides whether the epidemic burns out, did not cross the fork.

Deep Analysis

In plain English

Isolation means moving a confirmed patient to a treatment unit where they cannot infect others; contact tracing means finding everyone that patient was near before diagnosis and checking on them daily for 21 days, Ebola's incubation window. WHO's DON612 report shows these two efforts moving at very different speeds. Isolating patients, at about 44% of cases, still trails the 70% level modelling suggests is needed to bring the outbreak under control. Finding and following up contacts is going much better, at 83.2% in Ituri and 81% in North Kivu, up sharply from just 21% earlier. So contact tracers are finding people fast; the bottleneck is getting confirmed patients into a bed once found.

Deep Analysis
Root Causes

Patient isolation and contact-tracing follow-up measure two different constraints and should not be read as one problem. Isolation, at roughly 44%, is capped by how many treatment-unit beds exist in Ituri and North Kivu; DRC's Ministry of Health has not published a bed-expansion timeline to match the case count's 35% rise since 24 June.

Contact-tracing follow-up, at 83.2% in Ituri and 81% in North Kivu, is a workforce and trust problem instead: it depends on enough trained tracers reaching listed contacts before they disperse, and on those contacts believing cooperation carries no risk of forced hospitalisation.

The scale of that workforce challenge has grown alongside the outbreak: healthcare-worker infections alone have risen from 34 in mid-June to 102 now, thinning the pool of trained staff available to do the tracing.

What could happen next?
  • Risk

    If isolation stays below the 70% threshold CDC modelling flags while case counts keep rising at roughly 35% per nine-day period, DRC's treatment-unit bed capacity becomes the binding constraint on the outbreak's trajectory rather than case-finding.

First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

WHO· 5 Jul 2026
Read original →
Different Perspectives
IGWG co-chair Tovar da Silva Nunes
IGWG co-chair Tovar da Silva Nunes
The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.
Fraport
Fraport
The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.
European Centre for Disease Prevention and Control
European Centre for Disease Prevention and Control
ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.
Pan American Health Organization
Pan American Health Organization
PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.
Bangladesh Directorate General of Health Services
Bangladesh Directorate General of Health Services
The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.
Minapharm
Minapharm
The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.